

PHARMACEUTICAL INTELLECTUAL PROPERTY
from INNOVATORS to GENERICS

Table of Contents

Preface		7
Product strategy - which product to choose?		11
Generic competition and pharmaceutical innovation in the USA		21
1.	Genesis of the Act	24
A.	<i>The Movement to Generic Drugs</i>	24
B.	<i>The Case for Patent Term Extension</i>	33
2.	The Drug Price Competition and Patent Term Restoration Act of 1984	40
A.	<i>Pro-generic Provisions of the Act</i>	41
B.	<i>Pro-Brand Manufacturer Provisions of the Hatch-Waxman Act</i>	45
3.	Impact of the Act on the Marketing and Use of Generic Substitutes	48
A.	<i>Barriers to Generic Substitution</i>	49
B.	<i>Incentives to Generic Substitution</i>	54
4.	Impact of the Hatch-Waxman Act on Pharmaceutical Innovation	57
A.	<i>Averting Losses for Competition</i>	57
B.	<i>Lost Improvements in Drug Therapy Due to New Uses</i>	59
C.	<i>The Disincentive Created by the Statutory Reversal of Roche v. Bolar</i>	61
5.	Conclusion	64
IP for Generics in Japan		65
IP Laws (JAPAN)		66
1.	<i>PREFACE</i>	66
2.	<i>Patent Protection of New Drugs</i>	66
3.	<i>Term of Patent</i>	70

4.	<i>To what extent generics can be ready during the term of patent?</i>	70
5.	<i>The Exhaustion of Patent Right</i>	73
6.	<i>IP other than Patent Right: Design Right; Trademark; Unfair Competition</i>	74
Regulatory Laws (JAPAN)		74
1.	<i>Amendment of the Pharmaceutical Affairs Law</i>	74
2.	<i>Approval and License for Manufacture, Importation and Marketing</i>	75
3.	<i>Procedure for Marketing Approval</i>	78
4.	<i>Data Exclusivity: Re-examination Period</i>	80
5.	<i>NHI Price Listing</i>	81
6.	<i>Post-Marketing Safety Measure</i>	82
Patentability of patents on generics under the EPC		85
1.	Introduction	86
2.	Patents based on the European Patent Convention (EPC)	86
2.1	<i>Prospective amendments of the EPC – The EPC 2000</i>	87
2.2	<i>Filing and examination of European Applications at the EPO</i>	89
2.3	<i>Patentability of chemical/pharmaceutical inventions according to the EPC</i>	90
2.4	<i>Commercial applicability (Art. 57 EPC)</i>	101
2.5	<i>Sufficient disclosure (Art. 83 EPC) and clarity (Art. 84 EPC)</i>	101
3.	Patentability of specific types of claims	102
3.1	<i>Product-by-process claims</i>	102
3.2	<i>Screening methods and “reach-through” claims</i>	102
4.	Obtaining Patents through the national route	103
5.	Supplementary protection certificates (SPCs)	104
6.	Summary	105

Patent enforcement and freedom to act		107
1.	Patent Enforcement in Europe – Present Situation	108
1.1.	<i>Enforcing National Patents</i>	108
1.2.	<i>Enforcing EPC Patents</i>	109
2.	Specific Questions of Patent Enforcement in Germany	109
	<i>Litigation Procedure and Arguments for Defence</i>	109
3.	Fast Injunction Procedures in Germany	113
4.	Calculation of Damages in Patent Litigation Procedures in Germany	117
4.1.	<i>Introduction</i>	117
4.2.	<i>Damages for Patent Infringement - Compensation or Punishment?</i>	117
4.3.	<i>Methods of Calculating Damages</i>	118
4.4.	<i>Conclusion</i>	120
5.	Border Crossing Infringement	121
6.	Cross-Border Litigation	121
7.	Determination of Freedom to Operate	122
8.	Exemptions from Patent Protection	123
8.1.	<i>Experimental Use Privilege – Clinical Testing in Germany</i>	123
8.2.	<i>Case Law in Germany based on German Patent Act of 1968</i>	124
8.3.	<i>Case Law based on German Patent Act of 1981</i>	125
8.4.	<i>Implementation of EU Directive 2001/83/EC, as modified by Directive 2004/27/EC, in Germany</i>	127
9.	EU Action Plan for Improving of IPR Enforcement	128
Licensing in/out, Cross Licensing, Compulsory Licensing, and related Questions		133
1.	What is “Licensing”?	134
2.	Typical Kinds of License Agreements – Exclusive, Non-Exclusive, “Sole” Licenses	134

3.	Warranties	136
4.	Special Provisions Concerning Trademark Licensing	136
5.	Financial Terms in Licensing Agreements	137
6.	Specific Aspects of Licensing under EU Rules	139
7.	Compulsory Licenses and Use Orders	140
7.1	Governmental use order	140
7.2	Compulsory license	140
8.	Present Economic and Legal Standards of Countries entering WTO: Is now the Time for the Licensing Industry to Flourish?	141
9.	Summary	143
PatentPortfolioBuilding and Management		145
1.	Trade Secret or Patent - A Principle Choice	146
1.1.	<i>Inventions Derivable from Product Sold</i>	146
1.2.	<i>Inventions not Derivable from Product Sold</i>	146
2.	Trade Secrets and Pitfalls	147
2.1.	<i>Public Disclosure</i>	147
2.2.	<i>Patenting by a Third Party</i>	148
2.3.	<i>Remedies</i>	149
3.	Portfolio Strategies for Optimizing Costs	149
3.1.	<i>Homework</i>	149
3.2.	<i>Use of PCT</i>	150
3.3.	<i>National Patents or EPC?</i>	150
4.	Copyright Protection	151
5.	Conclusions	151
6.	Specific Aspects of Patent Portfolios in Pharmaceuticals	151

Valuation - Determining the Financial Value of Intellectual Property Rights		153
1.	Exploitation of Technology and Intellectual Property Rights (IPRs)	154
2.	Valuation of technology related IPRs	154
3.	Valuation of Patents	156
	<i>Employees' Invention Act (EIA) and Invention Value</i>	157
4.	Special Items	163
	<i>Know-How as Special Item</i>	
5.	Application in Practice	164
6.	Conclusions	165
Data exclusivity Legislation		167